Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue?
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
Read More
Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Read More
Most Retirees Overlook These Dow Dividend Stocks — They Pay More Than You'd Expect
Published: March 03, 2026 by: 24/7 Wall Street
Sentiment: Positive
The Dow Jones Industrial Average, commonly just called the Dow Jones or the Dow, includes 30 giant publicly listed companies with U.S.
Read More
Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?
Published: March 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company's pharmaceutical sales and has played an instrumental role in driving Merck's steady revenue growth over the past few years.
Read More
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
Published: March 02, 2026 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
Published: February 27, 2026 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will.
Read More
Merck Stock Jumps But Reddit Traders Are Getting Cold Feet
Published: February 26, 2026 by: 24/7 Wall Street
Sentiment: Positive
A giant in the healthcare space, Merck ( NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a neutral 43 this week.
Read More
Merck's New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.
Published: February 25, 2026 by: Barrons
Sentiment: Positive
Merck's two-drug HIV regimen matched Gilead's blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda's patent cliff.
Read More
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Published: February 25, 2026 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Read More
Merck creates separate oncology arm ahead of Keytruda patent loss
Published: February 23, 2026 by: Invezz
Sentiment: Neutral
Merck said on Monday that it will split its human-health operations into two separate divisions, a move designed to sharpen focus across its portfolio and ensure smoother launches of new medicines. The move comes as the drugmaker seeks to prepare for mounting sales pressure later this decade, driven by the looming loss of exclusivity for its top-selling cancer drug Keytruda, which will also expose it to lower-cost copycat competition.
Read More
Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugs
Published: February 23, 2026 by: Proactive Investors
Sentiment: Neutral
Investors gave a collective meh to news that Merck & Co Inc (NYSE:MRK, XETRA:6MK) is reportedly restructuring its human-health division, with shares marking time in premarket trading despite a reorganisation that signals the US drugmaker is bracing for the biggest revenue hit in its recent history. The Wall Street Journal reported on Monday that Merck plans to separate its human-health operations into two distinct divisions.
Read More
Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.
Published: February 23, 2026 by: Barrons
Sentiment: Positive
The drug maker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.
Read More
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Evolves Human Health Operating Structure to Support Portfolio Execution.
Read More
Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports
Published: February 23, 2026 by: Reuters
Sentiment: Positive
Drugmaker Merck is separating its human-health business into two divisions to offset pressures related to the patent loss of its top-selling drug Keytruda, the Wall Street Journal reported on Monday.
Read More
Merck is establishing a separate cancer unit. The reorganization of its pharmaceutical business is aimed at bolstering product launches ahead of a key patent loss.
Published: February 23, 2026 by: WSJ
Sentiment: Positive
The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.
Read More
Merck: This Cancer‑Drug Powerhouse Could Be a Core Dividend Holding for Decades
Published: February 22, 2026 by: The Motley Fool
Sentiment: Positive
The pharmaceutical giant is finding ways to navigate despite headwinds. This has helped the shares outperform the market over the past year.
Read More
Could Merck Stock Quietly Help Turn Steady Dividends Into a Millionaire Retirement?
Published: February 22, 2026 by: The Motley Fool
Sentiment: Positive
Merck is one of the world's largest drug companies. Although it isn't a player in the GLP-1 space, it has a well-supported dividend and a proven track record of dividend growth.
Read More
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Negative
BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.
Read More
Merck Indicates Better Growth Visibility in Post-Keytruda LOE Period
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Positive
MRK outlines solid long-term outlook with more than $70B opportunity beyond Keytruda LOE, backed by pipeline progress, new product launches and M&A deals.
Read More
Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors
Published: February 16, 2026 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Advanced Micro Devices is owned for its exceptional Corporate Resilience profile and attractive sustainability opportunity set in areas like the Digital Infrastructure build-out. Oracle stands out with a strong sustainability profile, offering notable opportunities in Digital Infrastructure, Education and the development of Enhanced Skills & Innovation.
Read More
MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell?
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Neutral
Merck stock has risen more than 7% in a month on a stronger long-term outlook, but 2026 headwinds, Keytruda patent risk and Gardasil slump keep it a Sell.
Read More
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Read More
Merck: The Spike Doesn't Make It Overvalued
Published: February 09, 2026 by: Seeking Alpha
Sentiment: Neutral
Merck has surged more than 50% in six months, underpinned by a robust asset portfolio and strong shareholder return strategy. Keytruda, MRK's top-selling drug, faces a 2028 patent cliff, but ongoing innovation and new approvals like Qlex aim to mitigate revenue risk. Despite Gardasil's recent sales decline, MRK's vaccine portfolio remains resilient, with Capvaxive sales up 460% to more than $1 billion annualized.
Read More
Merck: A Buy For 2026, But The Clock Is Still Ticking
Published: February 09, 2026 by: Seeking Alpha
Sentiment: Negative
Merck is rated Buy after extending Keytruda's patent protection to late-2029, delaying the anticipated patent cliff, and unlocking significant near-term value. The extended exclusivity creates a one-time cash windfall and enables deeper penetration of Keytruda QLEX, potentially adding $10/share in 'hidden alpha.' MRK's 40:30:30 strategy—QLEX migration, pipeline execution, and business development—offers a realistic path to offset Keytruda's eventual decline.
Read More
Wall Street Roundup: Risk Off
Published: February 06, 2026 by: Seeking Alpha
Sentiment: Negative
Risk-off sentiment is driving sharp sell-offs in Bitcoin and major software stocks, with investors reallocating away from stretched tech valuations. AI-driven CapEx arms race at Alphabet (GOOGL) and Amazon (AMZN) is sparking concerns about profitability and sector disruption, despite strong revenue growth.
Read More
Merck's Subdued 2026 Outlook: What it Means After Q4 Results?
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Negative
MRK posts conservative 2026 sales and EPS outlook, given acquisition charges. Keytruda, Animal Health and new drug launches are expected to drive 2026 growth.
Read More
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Read More
MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative
Merck tops Q4 EPS and sales estimates as Keytruda drives growth, but shares fall in pre-market trading as 2026 guidance disappoints.
Read More
Merck (MRK) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert Davis
- Employees 73000